Dexcom director plans sale of 1,550 shares

DEXCOM INC (DXCM) is the issuer for a notice filed on behalf of director Nicholas Augustinos to sell up to 1,550 shares of Dexcom common stock under Rule 144.

Rhea-AI Filing Summary

DEXCOM INC (DXCM) is the issuer for a notice filed on behalf of director Nicholas Augustinos to sell up to 1,550 shares of Dexcom common stock under Rule 144. The shares were acquired on May 8, 2026 through a vested RSU grant from Dexcom.

The proposed sale is listed for September 14, 2026 through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of approximately $130,231. The notice reports 377,360,765 Dexcom common shares outstanding, which is a baseline figure and not the amount being sold.

Key Figures

Shares to be sold: 1,550 shares Aggregate market value: $130,231 Shares outstanding: 377,360,765 shares +2 more

5 metrics

Shares to be sold 1,550 shares Common stock covered by the Rule 144 notice for Nicholas Augustinos

Aggregate market value $130,231 Approximate value of the 1,550 Dexcom common shares in the notice

Shares outstanding 377,360,765 shares Dexcom common shares outstanding as reported in the notice

Acquisition date of shares May 8, 2026 Date the shares were acquired via vested RSU grant

Proposed sale date September 14, 2026 Date listed for the planned sale of Dexcom common stock on NASDAQ

Key Terms

Rule 144, Vested RSU Grant, attorney-in-fact, Common Stock

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Vested RSU Grant financial

"Common Stock | 05/08/2026 | Vested RSU Grant | DEXCOM, INC."

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Common Stock financial

"Common Stock | Fidelity Brokerage Services LLC 245 Summer Street"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did DXCM director Nicholas Augustinos file in this Form 144?

Nicholas Augustinos filed a notice under Rule 144 to sell up to 1,550 shares of Dexcom Inc. common stock. The shares are proposed to be sold through Fidelity Brokerage Services LLC on NASDAQ.

How many Dexcom (DXCM) shares are covered by this Rule 144 notice?

The notice covers up to 1,550 shares of Dexcom Inc. common stock, with an aggregate market value of approximately $130,231 as indicated in the filing.

When were the DXCM shares to be sold by Nicholas Augustinos acquired?

The shares were acquired on May 8, 2026 through a Vested RSU Grant from Dexcom Inc., as stated in the securities-to-be-sold section.

When is the proposed sale date for the 1,550 DXCM shares?

The proposed sale date listed in the notice is September 14, 2026, with the shares to be sold on NASDAQ through Fidelity Brokerage Services LLC.

How many Dexcom (DXCM) common shares are reported outstanding in this notice?

The notice reports 377,360,765 Dexcom Inc. common shares outstanding. This figure is provided as context and is not the number of shares covered by the planned sale.

Who signed the Dexcom (DXCM) Form 144 filing for Nicholas Augustinos?

The filing is signed by Audrey Skillern, as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Nicholas Augustinos.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 09:43 AM Accepted by SEC EDGAR 09/14/2026 - 09:42 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001238485
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DEXCOM INC
SEC File Number	000-51222
Address of Issuer	6340 SEQUENCE DRIVE SAN DIEGO CALIFORNIA 92121
Phone	8582000200
Name of Person for Whose Account the Securities are To Be Sold	AUGUSTINOS NICHOLAS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Fidelity Brokerage Services LLC 245 Summer Street Boston MA 02110	1550	130231.00	377360765	09/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/08/2026	Vested RSU Grant	DEXCOM, INC.			1550	05/08/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Audrey Skillern, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Nicholas Augustinos
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)